Why the study?
Does physician-guided discontinuation of DAPT affect the risk of major adverse cardiac events in patients after percutaneous coronary intervention irrespective of high bleeding risk?
Does physician-guided discontinuation of DAPT affect the risk of major adverse cardiac events in patients after percutaneous coronary intervention irrespective of high bleeding risk?
Physician-guided discontinuation of DAPT appears safe regardless of high bleeding risk status, whereas unplanned disruption increases the risk of major adverse cardiac events.
Unplanned DAPT disruption may increase post-PCI MACE risk irrespective of bleeding risk; leaves open whether physician-guided discontinuation is safe, warranting randomized confirmation.
Patients at HBR remain at higher risk of adverse events. Disruption of DAPT is associated with an increased risk of major adverse cardiac events irrespective of the underlying bleeding risk. Physician-guided discontinuation of DAPT appears to be safe, irrespective of HBR.
No takes yet. Share an insight, caveat, or question.
Sorrentino et al. (2020) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: